Piper Jaffray analyst Danielle Brill notes that uniQure reported that the three patients in its Phase 2b trial for hemophilia-B gene therapy - AMT-061 - had an average Factor IX activity of 47% of the normal at 26 weeks. Considering that the average FIX activity was 38% of the normal at 12 weeks in the last update provided, the analyst finds these results "highly encouraging" and indicative of a durable and effective therapy that is producing stronger responses than previous competitors. Brill believes these results bode well for AMT-061's pivotal Phase 3 trial, which is recruiting right now, with topline data expected by year end 2020. Overall, the analyst says the company's AMT-061 is looking "clearly superior" to competition in Phase 2b Hemo-B update, and reiterates an Overweight rating and $80 price target on the shares.